Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 ...

Shares of HUTCHMED (NASDAQ:HCM) rose around 1.9% in premarket trading on Wednesday after the company reported positive Phase ...

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a planned China drug filing ...

Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — HONG KONG and SHANGHAI and ...

Investing.com -- HUTCHMED (NASDAQ:HCM) stock gained 1.9% in premarket trading Wednesday after the company announced that its Phase III trial of sovleplenib in patients with warm antibody autoimmune ...

Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias. Neil Minkoff, MD: Now, you had mentioned that there are other autoimmune ...

Autoimmune hemolytic anemia (AIHA) is a rare but clinically significant disorder in which the immune system mistakenly produces autoantibodies against red blood cells, leading to accelerated ...

Cold agglutinin disease is a condition that causes low red blood cell (RBC) counts. Symptoms can include fatigue, weakness, or shortness of breath. Cold agglutinin disease is a type of autoimmune ...

Autoimmune diseases in patients with CLL are separate from CLL, which calls for different treatments. Autoimmune complications “occur very commonly for people with CLL,” which is important for ...